After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...

AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in ...

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

For AbbVie, the 200-day moving average sits at $176.24, according to Benzinga Pro, which is below the current price of $189.49. For more on charts and trend lines, see a description here.